Abstract. To determine the direct effects of insulin\x=req-\ like growth factors (IGFs) on hormone release by the human pituitary gland, human foetal, adult normal and tumour pituitary tissues were maintained in culture for 2 to 4 weeks and tested with acute (3 h) exposures to different preparations of IGF peptides. Adult normal pituitaries and adenomas were tested with a semipurified preparation of IGFs, free of immunoreactive insulin, containing IGF-I and IGF-II in a ratio of approximately 1:4. Human foetal pituitaries were tested with the semipurified IGFs as well as more purified preparations of IGF-I and IGF-II. Culture media were assayed for hGH, hPrl, hACTH and hLH using specific radioimmunoassays.
pituitaries cultures responded to the semipurified IGFs (2\p=n-\25ngEq/ml for foetal and 2\p=n-\4 ngEq/ml for adult pituitaries) with a significant decrease in hGH release compared to basal (P < 0.01) whereas the GH-secreting pituitary tumours showed no effect when tested with from 2 to 25 ngEq/ml (n = 8, 129, ns) . The effect of IGFs on human foetal somatotrope activity was dose\x=req-\ related for both the semipurified IGFs (2\p=n-\25ngEq/ml, n = 16, 33) and IGF-I or IGF-II (10\p=n-\100ng/ml; n = 3, 18).
hPrl release was inhibited in the normal adult (n = 2, 12; P < 0.01) but not in the foetal (n = 2, 9; NS) pituitary cultures by 2\p=n-\4 ngEq/ml of the semipurified IGFs, while the Prl-secreting pituitary tumour cultures showed variable responses to 3\p=n-\4 ngEq/ml of the same IGFs preparation (a) suppression: n = 1, 14, P < 0.001; b) no effect: n = 3, 28, NS). hGH release was inhibited in one of the two mixed (GH-and Prl-secreting) tumours examined (n = 1, 10, P < 0.02) and unaffected in the other ( (Sakuma & Knobil 1970; Abrams et al. 1971 ; Abe et al. 1983; Mendelson et al. 1983) . Since GH appears to have no direct influence on somatotrope activity (Richman et (Guyda et al. 1981a . Thus, for every 1 ngEq of IGFs used, 0.5-1.7 µg of total protein were added. Further studies, using specific radioimmuno (Guyda et al. 1981b ) and radioreceptor (Guyda et (Goodyer et al. 1977 (Goodyer et al. , 1982 Marcovitz et al. 1982a (Fig. 1) . Foetal somatotrope cells also re¬ sponded to the semipurified IGFs with a decrease in basal GH secretion. All HFPs tested showed a response, the IGF effect was dose-related and statistically significant in the range of 4 -25 ngEq/ ml (Fig. 2) . IGF-I and IGF-II altered foetal soma¬ totrope activity in a parallel dose-related fashion, both peptides significantly suppressing GH secre¬ tion at a dose of 100 ng/ml (Fig. 2 (Table 2) . b) hPrl. The semipurified IGFs at 2-4 ngEq/ml significantly suppressed hPrl release from normal adult pituitary cells (n = 2, 12; < 0.01) (Fig. 1) , but had no significant effect on those foetal pitui¬ tary cultures that secreted high enough amounts of Prl to be considered reliable (> 10 ng/ml/3 h) (n = 2, 9; NS). Of the four prolactinomas tested with 3-4 ngEq of IGFs/ml, one showed a sig¬ nificant suppression of hPrl release (73.4 ± 1.7% (M ± SEM); < 0.001) while release remained un¬ changed for the other three (Table 2) . hPrl release from two mixed (GH + Prl-secreting) tumours was unaffected by the IGFs and there was no corre¬ lation between the hPrl and hGH responses to the semipurified IGFs in the mixed tumours (Table 2) . c) hACTH, hLH and hTSH. IGFs (2-10 ngEq/ml had no effect on hACTH or hLH releae by either Control IGFs (ngeq/ml) IGF-I (ng/ml) IGF-II (ng/ml) foetal ( = 10, 16) or normal adult (n = 2, 11) pituitaries ( Fig. 1; data Posner et al. 1978; Harley et al. 1980; Guyda et al. 198la (Goodyer et al. 1984b (Goodyer 1981; Goodyer et al. 1977 Goodyer et al. , 1982 Marcovitz et al. 1982 (Marcovitz et al. 1982b ).
Whether these abnormalities are a cause or an effect of tumour development and whether they are the result of a change at the membrane receptor (Goodyer et al. 1984a) 
